Objectives: The maintenance phase of bipolar disorder is arguably the most important. The aim of management during this time is to maintain wellness and prevent future episodes of illness. Medication is often the mainstay of treatment during this phase, but adherence to treatment is a significant problem. In recent years, long-acting injectable (LAI) solutions have been proposed, but these too have limitations. This paper discusses the options that are currently available and critically appraises the effectiveness of this strategy.
| INTRODUC TI ON
Bipolar disorder is a chronic and relapsing mental illness that manifests as episodes of depression, mania, or mixed states against a seeming background of wellness, termed euthymia. Episodes of depression bring with them distress, loss of productivity, and risk of suicide, while episodes of mania can lead to irreparable harm to interpersonal relationships, finances, and reputation. Furthermore, it is now recognised that episodes of illness, especially mania, can contribute to worsening of cognitive impairment among those with bipolar disorder, 1 underscoring the imperative to prevent relapses of the disorder.
The maintenance of mood stability and ensuring optimal functioning are the main goals of managing patients with bipolar disorder. For this, "mood stabilisers" are considered to be the first line medications. There is ongoing debate as to the definition of the term mood stabiliser 2, 3 and, for the purposes of this review, we will use it to refer to the anticonvulsants and lithium. Lithium is widely DOI: 10.1111/bdi.12698
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regarded as the gold standard medication for mood stabilisation. [4] [5] [6] However, perceived difficulties with prescribing lithium-its potential long-term side effects on renal and thyroid function and the fact that monitoring blood levels is essential-have limited its use and, although it provides robust prophylaxis for approximately a third of patients with bipolar disorder, 7 the remainder require alternative strategies, including anticonvulsants and antipsychotics.
The typical or first-generation antipsychotics (FGAs) were considered a first-line treatment for acute mania 8 and came to be used in maintenance treatment, not only because of their effectiveness in treating acute mania, but also due to the assumption that effective treatment in the acute phase would be effective in maintenance and concerns about relapse when withdrawn. When the second-generation antipsychotics (SGAs) were introduced, that are less likely to confer such a high risk of long-term motor side effects, they rapidly replaced the FGAs in the treatment of acute episodes and as maintenance, despite concerns about their long-term metabolic side effects. 9 More recently, long-acting injectable preparations (LAIs) of the SGAs are increasingly being used for maintenance. It is timely therefore to consider evidence regarding their effectiveness and side effects and the limitations of that evidence.
| The long-term management of bipolar disorder
The management of bipolar disorder falls into three distinct phases:
acute management, a continuation phase, and a maintenance phase 10 (see Figure 1) . Ideally, the treatments used in the acute phase are tapered down in the continuation phase, especially the adjunctive medications used to manage the behavioural disturbances associated with mania or a mixed state. The aim is to achieve mood stability, restore psychosocial functioning, and prevent relapse, while optimising medications to achieve minimal side effects. When stability has been achieved, in the maintenance phase, the aim is to maintain recovery and prevent recurrence of the illness. During this phase, further rationalisation of medications should ideally take place with the eventual aim (often not realised) of transitioning to monotherapy. The goal is to provide the patient with a simple regime of medication that will make adherence easier and minimise adverse effects.
11,12
| Non-adherence
There are serious consequences of bipolar relapses to either pole.
Despite evidence for relative effectiveness of a number of different drugs in preventing this, in practice, relapse is frequent. Approximately 10%-15% of patients with bipolar disorder have a severe and medication-resistant illness 13 but, more commonly, relapses occur as a consequence of medication non-adherence. It is estimated that around 40% of patients with bipolar disorder are not adherent to their medication, 14, 15 underscoring the fact that it is a significant problem in clinical practice and a key reason for bipolar patients relapsing.
Whatever the reason for non-adherence (see Table 1 ), relapse has adverse consequences for the patient and may contribute to a more severe and unstable course of illness 16 and worsening cognitive impairment. 1, 17, 18 Non-adherence should be reduced using psychosocial interventions (for example, psychoeducation and CBT), that foster better engagement and can significantly increase patient adherence. 19, 20 Despite these interventions being applied, additional strategies are often required, including considering the use of LAI antipsychotics.
| Long-acting injectable antipsychotics
Long-acting injectable antipsychotics (initially fluphenazine enanthate, then fluphenazine decanoate, and later flupenthixol decanoate) In light of these issues concerning non-adherence and the potential for LAIs to be used for prophylaxis in bipolar disorder, we undertook a critical review of the pertinent literature in order to develop clinical recommendations regarding the use of LAIs in the long-term management of bipolar disorder. 
| ME THODS
| RE SULTS
Generally speaking, open-label studies are less rigorous than double-blind, randomised, placebo-controlled trials, however, it is worthwhile noting that not all RCTs are equally robust; some studies and clinical trials are conducted principally for the purpose of regulatory approval, which can skew their design and limit their findings.
The characteristics of open-label studies and RCTs involving LAI antipsychotics are described in Tables 2 and 3 
| First-generation long-acting injectable antipsychotics
Small case series (eg, Naylor, Scott 28 ) and retrospective chart reviews (eg, White, Cheung, Silverstone
29
) suggested the utility of depot FGAs. One very small RCT (n = 33) comparing flupenthixol LAI with lithium showed no difference between treatments and in fact no change in number of episodes pre-and post-trial. 30 A second randomised controlled crossover (after 1 year) trial, in which flupenthixol vs placebo injection were added, also showed no beneficial effect of flupenthixol (judged by the number of days in hospital), but this was again a small sample (n = 15) 31 and, overall, the number of hospitalised days while the patients were in the trial was markedly fewer than the year before enrolling in the trial.
| Open-label and cohort studies of secondgeneration LAIs
Open-label studies are summarised in 36 Specifically, in psychotic, refractory bipolar disorder (n = 10), clinical outcomes were better on risperidone LAI over 3 years compared with the previous periods of treatment. 33 Savas et al, 32 Han et al, 37 and Vieta et al 38 all recruited patients only in a manic or mixed episode, and all showed a reduction in manic relapse on LAI risperidone.
Chan et al 39 in a larger study (n = 77 on LAI risperidone) classified patients into four groups on the basis of their medication historywhether they were on risperidone LAI or whether they were taking oral medication, and whether they were taking the medication or injection regularly. In both the adherent risperidone LAI and the non-adherent risperidone LAI groups, there was an improvement in several outcomes between the first (retrospective) year and the second (prospective) year of follow-up. There were also some improvements in the non-LAI groups. The main result appears to be that being followed-up in a study improves outcome. There does not appear to be data on adherence between the first and second 
| Randomised controlled trials of secondgeneration antipsychotic LAIs
We identified seven RCTs for maintenance in bipolar disorder. The studies differ in design to the extent that they are unsuitable for meta-analysis. Table 3 summarises their key characteristics. The trials divide into two different groups: (a) those which were specifically designed for regulatory approval with protocols agreed to by regulatory bodies and whose design is, to a large extent, governed by regulatory guidelines; and (b) those which were designed more as real-world clinical effectiveness trials, with scope to have a design which minimises exclusions and uses outcomes likely to be more relevant to clinical practice. The most important methodological issues are as follows.
| Patient characteristics at entry
Co-morbidity is an important aspect of bipolar disorder and, as with many RCTs, exclusion of co-morbidity represents a possible departure from usual clinical practice and a barrier to generalisation of the results. In particular, bipolar disorder is associated with a high rate (40%-50%) of substance abuse 44 and substance abuse is associated with a higher rate of poor response and rapid cycling. 45, 46 Of the RCTs, Calabrese et al 47 and Vieta et al 48 specifically excluded patients meeting criteria for any DSM-IV-TR diagnosis other than bipolar I disorder, which presumably excluded substance and alcohol abuse. Yatham et al, 49 Quiroz et al, 50 and MacFadden et al 51 only excluded recent drug or alcohol dependence, while Bobo et al 52 specifically note that patients were not excluded as long as bipolar disorder was the "principle condition" and Chengappa et al 53 had no exclusions for co-morbid conditions.
Relapse is more common in patients with frequent episodes.
However, patients with frequent episodes are more resistant to treatment (as they are difficult to stabilise 54, 55 ). Therefore, inclusion of patients with multiple episodes may decrease the likelihood of a "failed" trial-ie, a trial in which a drug that prevents mood episodes does not show superiority over placebo because of a low baseline rate of episodes. However, rapid cycling bipolar disorder may be significantly more resistant to treatment and, therefore, a successful mood stabiliser may not show superiority over a placebo in a rapid cycling population. all patients met DSM-IV criteria for rapid cycling.
With the exception of MacFadden et al and Bobo et al (which specifically recruited rapid cycling patients), studies recruited patients during a manic or mixed episode and, in fact, the majority of patients were in a manic episode. These patients are therefore more likely to have a predominantly manic pole of illness, making manic relapse more likely. Indeed, relapse was more common to manic, mixed or hypomanic states in these studies by two-to three times.
In MacFadden et al, depressive and manic episodes were roughly equal, while in Bobo et al depressive episodes occurred approximately three times as often. It is therefore not surprising that only this study found an advantage for LAI risperidone regarding relapse into depressive episodes.
| Duration of stabilisation and enrichment
Studies of relapse prevention in bipolar disorder have generally used a design which ensures stability at entry into the double-blind discontinuation treatment phase. This frequently involves treatment of The extent of enrichment is roughly proportional to the percentage of patients who survive from initial recruitment to randomisation. We propose that it is useful to quantify this and have done so in Table 3 survived to randomisation-around one third of the population recruited, whereas in Quiroz et al more than half the patients reached randomisation (ie, 1 in every 1.8). The index is higher when enrichment is greater. A related issue is the length of stabilisation. Here, the effect is more debatable since, while a longer phase may produce more enrichment, it may also reduce the risk of relapse, making it less likely that a difference in relapse will be seen post randomisation. Table 3 shows length of stabilisation period for each study. As noted, however, Calabrese et al used a variable stabilisation period based on a stringent definition of stability which may have affected enrichment and outcome. 
| Outcome measures
| Real-world outcomes
Three RCTs combine an RCT design with effectiveness principles. 49, 52, 53 All combined LAI risperidone with other mood stabilising medication and compared, with randomisation, to other antipsychotic medication plus mood stabilising medication. The study by
Chengappa et al appears to include a broad spectrum of patients, is not subject to enrichment, and has a primary outcome which incor- 
| Side effects
While the LAIs were generally well tolerated, especially when compared to oral SGAs, side effects to the LAIs were reported: weight gain (ranging from 5% to 18% for risperidone LAI compared with 1%-9% for placebo; and 18% for aripiprazole vs 12.9% for placebo), extrapyramidal side effects (5% for risperidone compared with 1%-9% for placebo; and 27.3% for aripiprazole vs 16.5% for placebo), and prolactin related side effects in 14% of those treated with risperidone LAI, with no prolactin-related side effects reported for the placebo group.
| Summary of results
1.
Most open-label studies show an advantage following treatment with LAI risperidone. This includes studies in rapid cycling bipolar disorder, psychotic bipolar disorder and, in one study, a reduction in depressive symptoms. 
5.
One study of monotherapy LAI risperidone vs placebo included a third arm of placebo injection and olanzapine. 48 In this study, the olanzapine (plus placebo injection) group had fewer mood episodes than the other two groups.
6.
While some studies included bipolar II patients, the evidence cannot be examined separately.
| D ISCUSS I ON
Since there are only seven RCTs investigating LAIs in relapse prevention in bipolar disorder, and they differ very significantly in methodology, this review is not a systematic or meta-analytic review.
Instead, we have examined evidence from these RCTs (and studies utilising other designs) and the key methodological issues in the RCTs which have been completed. From this, we present the following conclusions.
Trials of LAIs lie on a spectrum of efficacy vs effectiveness. to, and tolerate, the LAI involved, and outcomes which may miss clinically important differences between treatments. 58 Large RCTs suggest that LAIs (risperidone-three studies and aripiprazole-one study) are effective in delaying the time to relapse of any mood episode. However, this has been demonstrated in enriched samples, especially in the case of the single study of aripiprazole. In clinical practice, it is more likely that LAIs are going to be used for a group of patients who rarely meet such stringent criteria for stability and therefore this evidence may be less useful in this population.
A particular issue in the selection of patients is that non-adherent patients are less likely to consent to participate in an RCT and often meet exclusion criteria for clinical trials, and it is in these non-adherent patients that the greatest benefits may be expected.
Four of the open-label studies specifically included non-adherent patients, [32] [33] [34] [35] but there are no studies specifically in non-consenting patients, and the registry studies make no mention of whether patients "volunteered" into being administered an LAI. In this case, different methodologies may be more useful, for example, the mirror image study of Wu et al 41 and the examination of outcomes from a large Finnish data base, 42 or using more broad-based "outcome" studies of clinical cohorts. Non-adherent patients may also be more likely to suffer from substance or alcohol abuse/dependence or comorbid personality dysfunction. These patients are specifically excluded in five of the seven RCTs. Consideration for maintenance with LAIs is often on the basis not only of poor adherence but also active resistance, and these may in some jurisdictions be administered under a compulsory treatment order. Such patients are not included in these studies since they require consent and there is no separate consideration of this in the alternative designs of studies.
Non-adherent and non-consenting patients may be different in fundamental clinical characteristics and may respond differently compared with those represented in the clinical trials. Therefore, the effects of LAIs in these important groups of patients are unclear.
While there are clear benefits (lower risk of relapse) from treating patients using risperidone or aripiprazole LAIs, either as monotherapy or an adjunctive treatment, there are also significant side effects that need to be considered. The most notable side effects associated with the SGAs, as a class, are the metabolic side effects (obesity, hypertension, type II diabetes and metabolic syndrome), 59 although the risk of this is lower with aripiprazole than risperidone . 60 In addition to the metabolic side effects, there are significant side effects associated with risperidone-induced hyperprolactinaemia that can lead to long-term poor bone health and, in the short term, to menstrual dysfunction and sexual difficulties. There is less risk of weight gain (and metabolic side effects) with aripiprazole, but there is an increased risk of akathisia. These side effects need to be carefully managed in order to prevent long-term poor health outcomes and the potential for non-adherence (if the side effects, such as akathisia, are distressing for the patient) that would lead to a worsening of the patient's bipolar disorder.
| Recommendations for clinical practice
1. Where patients do adhere, or are likely to adhere to oral medication, the usual recommendations apply for maintenance treatment and LAIs are not indicated. 
7.
There is very limited evidence regarding the prevention of depressive episodes with LAIs. We do not recommend them for the prevention of depressive episodes.
8.
There is minimal evidence in bipolar II disorder and we do not recommend the use of LAIs in this situation, except in extreme circumstances such as rapid cycling, multiple hypomanic episodes, poor adherence, or failure to respond to other treatments.
9.
On the basis of extant evidence, risperidone would appear to be preferable to aripiprazole. However, in practice, it is seldom prescribed for bipolar disorder and is relatively poorly tolerated. It is advantageous with respect to first-generation LAIs because of lower risk of extra-pyramidal side effects, but its predilection for hyperprolactinaemia is a clear concern. Further evidence may well emerge regarding the efficacy and safety of LAI aripiprazole, paliperidone, and olanzapine, but is currently lacking. Therefore, clinicians will need to continue to use clinical judgement.
10.
LAIs may be used where patients have a preference to be on an LAI and are fully informed about the risks, benefits, costs, and alternatives to long-term treatment with an LAI.
11.
A key issue is whether LAIs have disadvantages compared with oral antipsychotics. This is not clear at present. We recommend that adverse effects should be monitored carefully, notably extrapyramidal side effects, raised prolactin and metabolic side effects. Weight, girth, triglycerides, serum glucose, and HbAIc should be checked at least every 6 months, so that appropriate measures can be taken to minimise any adverse outcomes.
Patients should also be routinely asked about potential "prolactin related" side effects (galactorrhoea, loss of libido, amenorrhea)
and, if present, have the serum prolactin measured.
12.
Where an LAI is prescribed, continued efforts should be made to engage in psychoeducation or specific psychotherapy in order to enhance stability and improve adherence. This may facilitate gradual discontinuation of the LAI over time. Other mood stabilising medication (ideally lithium) could be reintroduced during this time.
13. Calibrated syringes should be made available so that accurate proportions of standard doses of the LAI can be administered with the option of very gradual reductions over time.
| FUTURE RE S E ARCH
The largest studies of LAIs have been efficacy studies conducted by pharmaceutical companies. They do not apply to the patients most likely to benefit from LAIs and have significant methodological issues. Large, pragmatic clinical trials are required, similar to STEP-BD, 61 which examine the effectiveness of LAIs in the appropriate group of patients -those who are unable to adhere to oral treatment.
The relative effects of fluctuating compared with constant blood levels of second-generation antipsychotics are not clear and research should examine in more detail the relative long-term consequences of long-acting compared with oral antipsychotic treatment.
If constant levels improve illness control without increasing the risks of long-term adverse effects then LAIs may become a treatment which is preferred ahead of oral medication.
To date, only risperidone LAI has been investigated in several studies. Other LAI antipsychotics are available and could be more useful.
One strategy for evaluating the effectiveness of the LAIs would be to use mirror image studies as have been done for schizophrenia 
